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Abstract. Background and purpose: Increased body iron stores have been related to greater oxidative stress and brain injury in
clinical and experimental cerebral ischemia and reperfusion. We aimed to investigate the biological signatures of excitotoxicity,
inflammation and blood brain barrier disruption potentially associated with high serum ferritin levels-related damage in acute
stroke patients treated with i.v. t-PA.
Methods: Serum levels of ferritin (as index of increased cellular iron stores), glutamate, interleukin-6, matrix metalloproteinase-9
and cellular fibronectin were determined in 134 patients treated with i.v. t-PA within 3 hours from stroke onset in blood samples
obtained before t-PA treatment, at 24 and 72 hours.
Results: Serum ferritin levels before t-PA infusion correlated to glutamate (r = 0.59, p < 0.001) and interleukin-6 (r = 0.55,
p < 0.001) levels at baseline, and with glutamate (r = 0.57, p < 0.001), interleukin-6 (r = 0.49, p < 0.001), metalloproteinase-9
(r = 0.23, p = 0.007) and cellular fibronectin (r = 0.27, p = 0.002) levels measured at 24 hours and glutamate (r = 0.415,
p < 0.001), interleukin-6 (r = 0.359, p < 0.001) and metalloproteinase-9 (r = 0.261, p = 0.004) at 72 hours. The association
between ferritin and glutamate levels remained after adjustment for confounding factors in generalized linear models.
Conclusions: Brain damage associated with increased iron stores in acute ischemic stroke patients treated with iv. tPA may be
mediated by mechanisms linked to excitotoxic damage. The role of inflammation, blood brain barrier disruption and oxidative
stress in this condition needs further research.
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1. Background
The knowledge of new factors associated with a poor
response to thrombolysis in stroke patients may help
to conceive new strategies to improve the benefit of
this treatment. It has recently been shown that high
serum ferritin levels are associated with poor functional
outcome, hemorrhagic transformation and severe brain
edema in patients treated with i.v. tissue plasminogen
activator (t-PA) after ischemic stroke. These findings
indicate that increased body iron stores may offset the
beneficial effect of thrombolytic therapy [19].
The release of free iron from intracellular stores such
as ferritin as a result of cerebral ischemia, particularly
during reperfusion, catalyses the generation of the toxic
free radical hydroxyl which destroys cellular and mi-
crovascular integrity [16,27]. Experimental data sup-
ports the key role played by iron in brain and endothelial
injury in cerebral ischemia and reperfusion. Iron intake
has been associated with larger infarct volume, greater
reactive oxygen species (ROS) generation in brain and
peripheral vasculature, glutamate release and inflam-
matory response after middle cerebral artery occlusion
in the rat [2,18], whereas iron chelators, antioxidants
or ROS scavengers have shown neuroprotective effects
reducing infarct size, brain edema, ROS production and
metabolic failure in ischemia/reperfusion experimental
stroke models [9,11,24,26]. In addition, cellular bi-
ological studies in animal models have found a close
link between ROS generation in microvessels and as-
trocytic end-feet, increased matrix metalloproteinases-
9 (MMP-9) expression and blood brain barrier (BBB)
disruption [12].
Taking together, these findings suggest that genera-
tion of ROS during reperfusion, increased excitotoxic
damage, inflammation and BBB disruption might be
potential mechanisms of greater brain and endothelial
injury in ischemic stroke patients with iron overload
who are treated with i.v. t-PA. However, the underlying
pathophysiological basis of brain damage in these pa-
tients is unknown. The aim of this study was to inves-
tigate the biological signatures potentially associated
with high serum ferritin levels-related damage in acute
stroke patients treated with i.v. t-PA by measuring a se-
ries of biomarkers of excitotoxicity, inflammation and
endothelial injury that have been validated in previous
clinical studies.
2. Patients and methods
We studied acute ischemic stroke patients treated
with i.v. t-PA within 3 hours from symptom onset in
four university hospitals who accomplished the SITS-
MOST criteria [32]. Patients were continuously mon-
itored during the first 24 hours in the acute stroke
unit and were prospectively evaluated using brain CT,
and neurological and functional scales according to the
SITS-MOST registry during a follow-up period of 90
days. The protocol was approved by the Ethics Com-
mittees of the participating centers and informed con-
sent was signed by patients or their relatives. For the
purpose of this investigation, additional exclusion crite-
ria were prior disability (modified Rankin Scale (mRS)
>1), alcohol consumption  40g/day, current treat-
ment with iron, and known infectious, inflammatory or
cancer diseases at the time of treatment.
2.1. Clinical variables
Stroke severity was quantified before t-PA adminis-
tration and at 24 hours by using the National Institute of
Health Stroke Scale (NIHSS). Early neurological dete-
rioration was diagnosed when the NIHSS worsened 
4 points between baseline and 24h. Poor outcome was
defined as mRS score > 2 at 90 days.
2.2. Neuroimaging variables
CT scans were carried out on admission, and at 24–
36 hours after thrombolytic therapy. Early CT signs
of infarction were evaluated on admission, and infarct
volume, hemorrhagic transformation (HT) and brain
edema were assessed at 24–36 hours. HT was classified
as hemorrhagic infarction, and parenchymal hematoma
(PH) according to the ECASS-2 criteria [17]. PH was
considered as being symptomatic when it was associat-
ed with early neurological deterioration. Severe brain
edema was diagnosed if there was extensive swelling
causing any shifting of the midline structures. Hypo-
density volume was calculated using the formula 0.5 x
a x b x c, where a and b are the largest perpendicular
diameters, and c is the slice thickness. CT scans were
evaluated by investigators blinded to the laboratory de-
terminations and clinical outcome.
2.3. Laboratory determinations
Serum samples were taken immediately after admis-
sion (within 3 hours of stroke onset and before the t-PA
treatment), at 24 hours and at 72 hours after the t-PA
bolus infusion, and they were stored at −80◦C. Serum
ferritin levels, as an index of body iron stores, were de-
termined by electrochemiluminescence immunoassay
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using an analyzer ELECSYS 2010 (Roche Diagnostics
GmbH); glutamate levels, as a biomarker of excitotox-
icity, were determined by HPLC, using the Waters Pico
Tag Chemistry Package for HPLC amino acids anal-
ysis; interleukin-6 (IL-6), as an index of inflammatory
response, were determined by IMMULITE 1000 Sys-
tem, Diagnostic Products Corporation (DPC), USA;
and finally, c-Fn and MMP-9 levels, as BBB disruption
biomarkers, were determined with commercially avail-
able quantitative sandwich enzyme-linked immunoab-
sorbent assay kits obtained from Biohit Plc, Finland,
and Biotrack, Amersham Pharmacia, UK, respectively.
Biomarker concentrations were measured in a central
laboratory by investigators blind to the clinical outcome
and neuroimaging findings. Clinical investigators were
unaware of the laboratory results until the end of the
study, once the data base was closed.
2.4. Statistical analyses
Categorical variables were expressed as proportions
and compared by using the χ2 test. Continuous vari-
ables were expressed as the mean and SD when the
variable distribution was normal or median and quar-
tiles when it was not normal, and compared by the
Student’s t-test or the Mann-Withney test, respectively.
Spearman’s coefficient was used to analyze the correla-
tion between serum ferritin levels, biomarker concen-
trations and other continuous variables. Receiver op-
erating characteristic (ROC) curves were configured to
establish cut-off points of ferritin level that optimally
predicted the occurrence of poor outcome. According-
ly, the impact of serum ferritin levels on outcome, HT
and brain edema formation was assessed by logistic re-
gression analysis adjusting for age, stroke severity and
other baseline variables related in the univariate anal-
ysis (p value < 0.1). To assess the influence of base-
line ferritin levels on the serum concentrations of brain
injury biomarkers, general linear models for repeated
measurements were used and they were adjusted for
variables related to baseline ferritin concentrations with
a p value < 0.05.
3. Results
A total of 134 patients treated with t-PA were includ-
ed in this study. Reasons for exclusion and baseline
characteristics of included patients have been recent-
ly reported [19]. Blood samples were obtained in all
patients at baseline, in 130 patients at 24 hours (one
patient died before, and samples from 3 patients were
unavailable) and in 118 patients at 72 hours (3 patients
died, 6 were discharged before the third day, and sam-
ples from 9 patients were unavailable). No patients
were lost of follow-up.
3.1. Clinical outcome, neuroimaging findings and
biomarkers of brain injury
At 3 months, poor outcome was recorded in 73 pa-
tients (54.5%), and mortality in 18 patients (13.4%).
CT at 24–36 hours showed no signs of infarction in
10% of patients. Median hypodensity volume was 19
cc [3,80]. HT was observed in 27 (20%) patients, hem-
orrhagic infarction in 15 and PH in 12 patients (symp-
tomatic in 4), and severe cerebral edema was found in
15 (11.2%) patients.
Table 1 shows the baseline characteristics, laboratory
parameters, and brain injury biomarkers in subgroups
classified by clinical outcome at 90 days, presence of
PH, and severe brain edema at 24–36 hours after treat-
ment. Baseline serum ferritin, glutamate, IL-6, c-Fn
and MMP-9 levels were significantly higher in patients
with poor outcome, PH and severe brain edema in uni-
variate analyses (Table 1).
As previously reported the adjusted odds ratios of
poor outcome, PH and severe brain edema for ferritin
levels> 79 ng/mL were 117 [95%CI, 24.4–559.5], 4.2
[95%CI, 0.8–22], and 6.4 [95%CI, 1.3–32], respective-
ly [19].
3.2. Serum ferritin and biomarkers of brain injury
Serum ferritin profile during the first 72 hours
showed a parallel slight increase in both outcome
groups (data showed in ref. 19). Baseline serum fer-
ritin concentrations were significantly higher in patients
with diabetes mellitus (p = 0.041), early CT signs of
infarction (p < 0.001), and in non-lacunar stroke sub-
type (p = 0.005), but no differences were found for sex
and other vascular risk factors. Baseline ferritin values
correlated with NIHSS at admission (r = 0.489, p <
0.001) and at 24 hours (r = 0.747, p < 0.001), and with
infarct volume (r = 0.663, p < 0.001). No correlations
were found with age, systolic and diastolic blood pres-
sure, body temperature, serum glucose, platelet count,
leukocytes, aPTT and time from symptoms onset to
t-PA bolus.
Table 2 shows the correlations between ferritin levels
at baseline and the biomarkers of brain injury measured
at different intervals. A significant correlation was
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Table 2
Correlation coefficients between baseline ferritin levels and the biomarkers of brain injury
Biomarkers Baseline 24 hours 72 hours
Glutamate, µM/L r = 0.589, p < 0.001 r = 0.507, p < 0.001 r = 0.415, p < 0.001
IL-6, pg/mL r = 0.549, p < 0.001 r = 0.465, p < 0.001 r = 0.359, p < 0.001
c-Fn, mg/L r = 0.154, p = 0.075 r = 0.268, p = 0.002 r = 0.096, p = 0.301
MMP-9, ng/mL r = 0.114, p = 0.190 r = 0.234, p = 0.007 r = 0.261, p = 0.004
Table 3
Adjusted baseline ferritin concentrations for serum biomarker
levels at repeated measurements
Models β (95% CI) p
Model 1
Serum glutamate, µM/L
At baseline 0.42 (0.25, 0.59) < 0.001
At 24 hours 0.26 (0.11,0.42) 0.001
At 72 hours 0.16 (0.02,0.30) 0.020
Model 2
Serum IL-6, pg/mL
At baseline 0.014 (−0.011, 0.03.9) 0.233
At 24 hours 0.014 (−0.032, 0.060) 0.541
At 72 hours −0.007 (−0.080, 0.068) 0.861
Model 3
Serum c-Fn, mg/L
At baseline 0.001 (−0.003, 0.004) 0.640
At 24 hours 0.003 (−0.001, 0.006) 0.148
At 72 hours 0.001 (−0.003, 0.004) 0.791
Model 4
Serum MMP-9, ng/mL
At baseline 0.036 (−0.140, 0.074) 0.521
At 24 hours 0.018 (−0.078, 0.110) 0.710
At 72 hours 0.130 (0.028, 0.230) 0.013
The models were adjusted for history of diabetes mellitus, early
CT signs, stroke severity and non-lacunar stroke subtype.
found between baseline ferritin levels and the concen-
trations of glutamate and IL-6 on admission, at 24 and
at 72 hours. Baseline serum ferritin levels did not cor-
relate with either c-Fn or MMP-9 on admission, where-
as a slight correlation was found between baseline fer-
ritin and c-Fn and MMP-9 levels at 24 hours (Fig. 1),
and between baseline ferritin and MMP-9 levels at 72
hours.
The association between ferritin and glutamate levels
remained significant after adjustment for diabetes mel-
litus, early CT signs, stroke severity, and non-lacunar
stroke subtype in generalized linear models for repeated
measurements. However, IL-6, cFN and MMP-9 levels
at repeated samples lost their association with baseline
ferritin after adjustment for covariates (Table 3).
4. Discussion
High serum ferritin concentrations, used as an in-
dex of increased body iron stores, have been previ-
ously reported to be associated with poor outcome,
parenchymal hematoma and severe brain edema in this
same sample of patients [19]. In this secondary study,
we have investigated the biological signatures of brain
damage associated with increased body iron stores by
analyzing a series of accepted biomarkers of brain in-
jury. Baseline ferritin levels showed a moderate corre-
lation with glutamate and IL-6 and a slight correlation
with the biomarkers of BBB injury. Importantly, the
association with high glutamate levels over the first 72
hours after admission remained independent of other
related clinical variables. These findings support that
excitotoxic damage might mediate the greater brain in-
jury found in ischemic stroke patients with increased
ferritin levels that are treated with t-PA.
The tested biomarkers have widely been assessed in
previous studies and validated as early and good bi-
ological predictors of brain and BBB injury [3,4,6,7,
21,28,29,31]. Furthermore, we have recently demon-
strated that high levels of glutamate in the peripheral
blood are associated with ischemic lesion growth on
diffusion-weighted MRI in the acute phase of ischemic
stroke [5]. In fact, the present study confirms that
elevated serum concentrations of glutamate, IL-6, c-
Fn and MMP-9 on admission are associated with poor
functional outcome, PH and severe brain edema in pa-
tients with ischemic stroke treated with iv. t-PA. The
association between high ferritin levels and glutamate
release in serum and cerebrospinal fluid was also found
in a series of patients with acute stroke not treated with
thrombolysis [10]. Enhanced glutamate-mediated ex-
citotoxicity was proposed as one of the mechanism of
increased body iron stores related injury in cerebral is-
chemia since, in neuronal cultures, glutamate release
is significantly increased by systems leading to free
radical formation [22,25], whereas antioxidants have
shown a neuroprotectiveeffect by decreasing glutamate
release and subsequent excitotoxicity in experimental
stroke models [14].
The present findings are in line with experimental
data in a rat model of permanent MCA occlusion after
high iron intake which showed 66% greater infarct vol-
ume, and higher serum levels of glutamate, IL-6, tu-
mour necrosis factor-α and thiobarbituric acid reaction
substances (TBARS) in comparison with those of ani-
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Fig. 1. Significant correlations between serum ferritin and serum biomarkers concentrations at baseline (A) and at 24 hours (B). Correlation
coefficients are shown in Table 2.
mals receiving a normal diet [2]. Therefore, biomark-
ers of oxidative stress, excitotoxicity and inflammation
could be surrogates of the importance of iron-related
brain damage after cerebral ischemia. These biomark-
ers are likely reflecting distinct mechanisms of injury
which are interconnected, so it is difficult to delineate
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the role of each of them.
The deleterious effects of iron in the neurovascular
unit might be aggravated by the t-PA-induced excito-
toxicity and MMP-9 overexpression [15,23,30], and by
a higher free radicals generation from oxygen after t-
PA-induced reperfusion [1], leading to HT and edema.
In fact, although iron overload in animals has not been
associated with changes in cerebral total iron levels [2],
iron accumulates in the endothelial cells [18] and, in
ischemia-reperfusion stroke models, it is significantly
increased in some brain areas such as the hippocam-
pus along with BBB disruption, lipid peroxidation and
apoptosis [13]. The lack of an independent association
of serum ferritin values with the markers of inflamma-
tory response and BBB disruption is not in favor of an
enhancing effect of iron overload on the mechanisms
underlying the microvascular disruption after cerebral
ischemia in patients treated with trhombolytic drugs.
However this hypothesis needs to be tested in experi-
mental studies.
This study has a number of limitations. First, serum
biomarkers do not necessarily reflect the importance
of the molecular processes in the ischemic brain, and
may be influenced by the acute phase reaction associ-
ated with cerebral ischemia. However, serial determi-
nations have not shown a significant increase of serum
ferritin levels 4h after experimental stroke, and incon-
sistent results at 24 hours [20]. Moreover, in the present
study, like in previous reports, the association between
high ferritin levels, outcome variables and some brain
injury biomarkers was independent of stroke severity
and other prognostic variables. Second, we did not
measure molecular markers of oxidative stress, which
have not been widely validated in clinical studies [8],
so the potential effect of increased iron stores on ROS
generation is unknown in patients with acute ischemic
stroke. Third, the influence of arterial recanalization on
the biological response has not been evaluated, since
we did not perform systematic transcranial Doppler ul-
trasound. Finally, the clinical design of this study does
not allow the investigation of the possible synergistic
neurotoxic effect of high iron stores and t-PA in acute
stroke, which should be investigated in experimental
models.
In conclusion, the present findings indicate that brain
damage associated with high serum ferritin levels in
acute ischemic stroke patients treated with iv. tPA
may be mediated by mechanisms linked to excitotoxic
damage. The role of inflammation, BBB disruption
and oxidative stress in iron-related brain damage needs
further research.
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